The Complex Immunological Pathogenesis Behind COVID-19

27/04/2020

Clinicians, scientific communities, biotech companies, public health agencies alongside with governments around the world are working to support the fight against the current COVID19 pandemic. Despite these huge efforts, we do not have a detailed picture of the new coronavirus, including the immunopathogenesis of the disease. This review tries to...

Webinar – What are the crucial factors to perform a successful NGS run?

23/04/2020

Join us for a Webinar on Tuesday, April 27 with Libor Kolesár (Senior Field Application Scientist, Omixon) who will be talking about the common causes of NGS library preparation, sequencing of Holotype HLA and how to troubleshoot them. Agenda: 🔸 Very low library concentration 🔸 Overloading of...

Omixon Academy 2020 – HLA (Human Leukocyte Antigen) and its Basic Immunological Roles

22/04/2020

During the COVID-19 pandemic, Omixon is committed to continuously provide resources and educational material to the HLA community. We have compiled a list of topics that both beginners and advanced users could find beneficial. This time, Omixon invites you to join our next educational session to learn more about HLA (Human Leukocyte...

Omixon Founder, Attila Bérces Returns as CEO, Aims to Roll-Out New Products

20/04/2020

We are happy to announce that Omixon’s founder and chairman Dr. Attila Bérces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialization of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017. In concert between the incoming and outgoing CEOs, as...

Update Regarding our Operations during COVID-19

20/04/2020

Dear Customers, Due to the SARS-CoV-2 outbreak, we have already notified you about changes in our operations. Please see below further amendments we would like to inform you about: Our Global Logistics Team continues all activities, but considering the service quality and transit unpredictability of all freight companies, Omixon decided to...